Warrant inducement: why holders exercise early and receive new warrants

Start with the deal in one sentence

A warrant inducement is a negotiated deal in which a company persuades holders of existing warrants to exercise them now, for cash, and in return gives those holders something new, usually a fresh batch of warrants.

The term is not a statutory category. It is the name issuers and placement agents use for this structure, and in filings it usually appears as an "inducement letter" or "inducement agreement" filed with a Form 8-K.

For a trader the important point is simple: one announcement contains two separate share events. Existing warrants become common shares soon, and new warrants create a fresh pool of potential shares for later.

Why would anyone exercise early?

A holder normally has no reason to exercise a warrant early. Exercising gives up the option's remaining time value and requires cash now. So the company has to offer something:

• A lower exercise price on the existing warrants. Many inducement deals reduce the old strike so holders pay less per share. The example below did not do this, which is why you must read the terms instead of assuming them.
• New warrants. The company issues replacement warrants, often covering more shares than were exercised. The ratio of new warrant shares to exercised shares is commonly called coverage.
• Other terms. Longer life, a different exercise price, or registration rights for the new warrant shares.

The company gets cash immediately, without waiting for the market price to rise above the old strike. The cost is a larger share count today and a new layer of potential shares tomorrow.

The two halves, in ledger terms

Use the habits from Lessons 2 and 7:

The first half is usually dilution you can count: the filing often states shares outstanding before and after. The second half is a scenario: new warrants may need stockholder approval, an effective registration statement, or a price above the strike before they matter.

Walkthrough: Co-Diagnostics, Form 8-K filed July 31, 2026

Source: Co-Diagnostics, Inc. Form 8-K (event date July 30, 2026), filed with the SEC on July 31, 2026. All figures below are quoted or derived from that filing unless a later filing is cited. FennEdge has not checked every filing after October 5, 2026.

Step 1: identify the existing warrants

The 8-K describes existing warrants covering 1,702,362 shares, originally issued on May 21, 2026, with a five-year term and a $1.571 exercise price. The holders agreed to exercise all of them for cash at that same $1.571 price. In this deal the old strike was not reduced.

Expected gross proceeds: about $2.67 million, before placement-agent fees and expenses. Check it yourself: 1,702,362 × $1.571 ≈ $2,674,411.

Step 2: read the share count before and after

The filing states shares issued and outstanding were 5,277,846 immediately before the transaction and 6,980,208 after it, including the closing:

6,980,208 − 5,277,846 = 1,702,362 new shares

1,702,362 ÷ 5,277,846 ≈ 32.3% increase in shares outstanding

This is the countable half. The closing was expected on or about August 3, 2026, and a later proxy statement refers to the new warrants as issued on August 3, 2026.

Step 3: size the new warrants

As consideration, the company agreed to issue new warrants for 3,404,724 shares at a $1.56 exercise price:

3,404,724 ÷ 1,702,362 = 2.0 → 200% coverage

Before you add them to anything, read their conditions:

• They are not exercisable until stockholders approve the exercise under applicable Nasdaq rules. The 8-K does not name the rule number.
• Once exercisable, their term is five years from the date of that approval.
• They include a 4.99% beneficial-ownership limit (9.99% if a holder elected it), so a single holder cannot convert its entire position at once.
• Cashless exercise is available if no registration statement for the underlying shares is effective.

If every new warrant were eventually exercised for cash, the company would receive 3,404,724 × $1.56 ≈ $5.31 million and deliver 3,404,724 more shares. That is a conditional scenario, not a fact.

Step 4: follow the paper trail

The inducement created obligations with deadlines. Here is what the public record showed when we checked on October 5, 2026:

So, as of October 5, 2026: the shares from the exercised warrants are part of outstanding; the resale path for the new-warrant shares is effective; the stockholder approval that makes the new warrants exercisable had not yet been reported. Remember Lesson 3: an effective resale registration is a sales path, not an issuance.

Step 5: note the side terms

Two more details shape near-term supply:

• The company agreed not to issue common stock or equivalents, or file other registration statements, until August 31, 2026, subject to exceptions. That is a contract gate of the kind Lesson 8 covers.
• The placement agent receives a 7.0% cash fee on gross exercise proceeds plus $50,000 of expenses.

How to read the next inducement 8-K

Use the same checklist every time:

1. Existing warrants: how many shares, original issue date, old exercise price, new exercise price if reduced.
2. Cash: gross proceeds and fees. Divide gross proceeds by exercised shares to confirm the price.
3. Shares outstanding before and after, with the as-of date.
4. New warrants: share count, coverage ratio, exercise price, term, and when they become exercisable.
5. Gates: stockholder approval, ownership blockers, registration of the underlying shares.
6. Side terms: standstill or no-issuance periods, and resale registration deadlines.

Then write your result in two lines, never one: "Outstanding rose by X as of date D" and "Up to Y additional shares are possible if conditions C are met."

What an inducement does not tell you

It does not tell you whether the stock will rise or fall, whether holders will sell the new shares, or whether stockholders will approve the new warrants. It tells you the company chose immediate cash over waiting, and what that choice did to current and potential share counts.

Remember one line

An inducement is two events: old warrants become shares now, and new warrants become a fresh potential pool with its own conditions.

Read the primary sources

• Co-Diagnostics, Inc. Form 8-K filed July 31, 2026 (inducement letter)
• Co-Diagnostics, Inc. Form S-3 filed August 24, 2026 (resale of new-warrant shares)
• Co-Diagnostics, Inc. preliminary proxy filed September 21, 2026
• SEC: Form 8-K instructions, including Item 3.02 unregistered sales of equity securities